NCT05940558View on ClinicalTrials.gov

Safety and Efficacy of MBF-118 in Patients with Crohn Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

September 10, 2024

Study Completion Date

September 10, 2024

Conditions

Crohn Disease

Interventions

DRUG

MBF-118 oral capsules

MBF-118 oral capsules PPAR gamma receptor partial agonist

Trial Locations (1)

15706

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

Sponsors

Lead Sponsor

Medibiofarma S.L.

All Listed Sponsors

lead

Medibiofarma S.L.

INDUSTRY

NCT05940558 - Safety and Efficacy of MBF-118 in Patients with Crohn Disease | Biotech Hunter | Biotech Hunter